key: cord-0686410-2dcnsxko authors: Yimer, Getnet; Ekuadzi, Edmund; Fasinu, Pius; de Melo, Andreia Cristina; Pillai, Goonaseelan (Colin) title: Traditional medicines for COVID‐19: Perspectives from clinical pharmacologists date: 2021-07-16 journal: Br J Clin Pharmacol DOI: 10.1111/bcp.14981 sha: b7d134427060def2a57782c40be1921dd8d3734b doc_id: 686410 cord_uid: 2dcnsxko There has been high interest in the use of traditional medicines for COVID‐19 from early in the course of the pandemic. Significant advances in the science of ethnopharmacology have helped to introduce chemical entities identified from natural sources into modern medicine. However, the wider integration of natural products into the modern drug discovery process will require enhanced collaboration amongst the pharmaceutical industry, academic research units, regulatory bodies, ethics review committees and local, regional, continental and international organizations. Revisiting this topic holds promise of benefit for both the current and future pandemics. There has been high interest in the use of traditional medicines for COVID-19 from early in the course of the pandemic. Significant advances in the science of ethnopharmacology have helped to introduce chemical entities identified from natural sources into modern medicine. However, the wider integration of natural products into the modern drug discovery process will require enhanced collaboration amongst the pharmaceutical industry, academic research units, regulatory bodies, ethics review committees and local, regional, continental and international organizations. Revisiting this topic holds promise of benefit for both the current and future pandemics. Significant advances in the science of ethnopharmacology has helped to introduce single chemical entities, in contrast to composite natural product source, into modern medicine. 7 A large number of modern-day therapies have had their documented origins in natural products. These include the popular antimalarial drugs, quinine and artemisinin from Cinchona and Artemisia species, respectively; the heart failure treatment, digoxin from Digitalis species; the important pain relief agents codeine and morphine from Paperver species; anticancer drugs vincristine and vinblastine from Catharanthus roseus; and the pre-surgery medication, atropine from Atropa belladona. 8 In this paper, we present our views as clinical pharmacologists, and we acknowledge our bias in having been trained in conventional drug use, but highlight our respect and optimism for the potential role of traditional medicines in the current and future pandemics. Our purpose is to invite comment, critique and alternate viewpoints. As scientists, we recognize the benefit of traditional medicines but have been conditioned to seek standards, procedures and investigations that would provide confidence in short and long-term safety and efficacy claims that align with our own training. This raises a number of questions to be considered: • Can claims of efficacy and safety be underwritten by the scientific methods that are already available for conventional drug research and development? • What are the potential social, economic, political and community usage implications if traditional medicine is required to strictly follow the procedures required by conventional science? • How could modern and traditional healthcare practitioners learn from each other to benefit their common patient base? At first blush, the conventional science-based approach to identifying new therapies seems incongruent with the process by which traditional medicine is practiced. African traditional medicine provides holistic treatment. The techniques often derive from the aetiology of disease, as conceived by the practitioners: herbalists, traditional birth attendants, bone setters, diviners, faith healers and spiritualists. Their belief is that diseases may be caused by spiritual and esoteric causes as well as physical and psychological triggers. 9 Following diagnosis, a treatment usually consisting of a polyherbal remedy is prescribed. In some cases, individual compounds are responsible for the reputed pharmacological effect. However, in many cases, the observed pharmacological effects is due to a mixture of different compounds as well as the holistic approach of the practitioner. The integration of African natural products into the modern drug discovery process will require enhanced collaboration among the pharmaceutical industry, academic research units, regulatory bodies, ethics review committees and local, regional, continental and international organizations. This aligns with the compromise process that some experts 10, 11 have promoted to facilitate the integration of traditional and orthodox medicine by firstly recognizing claims of efficacy and then attempting to collect as much clinical experience data as possible, while moving backwards through laboratory evaluations, preclinical experiments and targeted clinical studies based on the learnings. We realize that these represent formidable ambitions and suggest that assessments might be prioritized for those traditional therapies that are widely used or have popular support and evaluate these in clinical trials. Recent reviews of African natural products that have therapeutic potential for COVID-19 provide useful starting points. 5, 12 We conducted an informal assessment of the COVID-19 clinical trials registered on https://clinicaltrials.gov and https://pactr.samrc. or "not yet recruiting," thus eventual trial execution and dissemination of the results is uncertain. Notwithstanding the succinct and often incomplete nature of the entries on these registries, we were encouraged to note hospital-based studies and study processes that might increase confidence in the trial outcomes, for example, blinding, randomization and comparisons to standard of care. However, we acknowledge that the rigour and requirements of clinical trials are likely to be unaffordable for most investigators and countries but suggest that the approach outlined in Table 1 , while expediting the process, might inform research for future pandemics. • The overall goal should be to emphasize safety while establishing evidence of efficacy and quality assurance of approved products. The natural product extract has to be standardized based on an active constituent or group of active constituents. 9,10 b Experience with conventional therapies suggests that while the parent drug might be important for efficacy, the safety signals are often driven by the metabolites or additives. The role of plants in traditional medicine and current therapy Availability, accessibility, acceptability, and adaptibility: four attributes of African ethno-medicine Integrating herbal medicine into mainstream healthcare in Ghana: clients' acceptability, perceptions and disclosure of use Therapeutic potentials of antiviral plants used in traditional African medicine with COVID-19 in focus: a Nigerian perspective Ethnomedical and ethnobotanical investigations on the response capacities of Guinean traditional health practioners in the management of outbreaks of infectious diseases: the case of the Ebola virus epidemic News from Tartary: an ethnopharmacological approach to drug and therapeutic discovery Plant-derived natural products in drug discovery and development: an overview An alert on the incautious use of herbal medicines by sub-Saharan African populations to fight against the COVID-19 Artemisia Spp. derivatives for COVID-19 treatment: anecdotal use, political hype, treatment potential, challenges, and road map to randomized clinical trials Ethnomedicinal herbs in African traditional medicine with potential activity for the prevention, treatment, and management of coronavirus disease Traditional medicines for COVID-19: Perspectives from clinical pharmacologists The authors are grateful for the advice of the core team members of the Clinical Pharmacology and Drug Candidates Working Group of the COVID Clinical Research Coalition. Goonaseelan (Colin) Pillai https://orcid.org/0000-0002-5658-3837